Company facts
- Founded
- 2025
- Headquarters
- Switzerland
About
Nanolynx Biologics is developing conditionally active nanobody-drug conjugates (CA-NDCs), a first-in-class therapeutic modality designed for tumor-selective activation, deep penetration, and reduced systemic toxicity. Powered by our proprietary IntelliBody™ platform, we overcome the fundamental biological and safety li…